ArticleThe Kaohsiung journal of medical sciences2025
KLF1 Promotes Non-Small Cell Lung Cancer Cell Proliferation and Invasion by Upregulating the LINC02159/DYNC1H1 Pathway.
Article in The Kaohsiung journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- KLF1 Promotes Non-Small Cell Lung Cancer Cell Proliferation and Invasion by Upregulating the LINC02159/DYNC1H1 Pathway.The Kaohsiung journal of medical sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC) is a common and fatal malignancy. This study aimed to elucidate the mechanism of Kruppel-like factor (KLF1) in NSCLC progression. Clinical samples were collected, after which the expression levels of KLF1, LINC02159, and dynein cytoplasmic 1 heavy chain 1 (DYNC1H1) in tissues and cells were initially detected, and NSCLC cell proliferation and invasion were measured when KLF1 was up- or downregulated. The binding relationships among KLF1, the LINC02159 promoter, DYNC1H1, and serine and arginine-rich splicing factor 1 (SRSF1) were analyzed. The colocalization of LINC02159 and SRSF1 was verified. DYNC1H1 stability upon actinomycin D treatment was assessed. Combined experiments were designed to confirm the interaction of the LINC02159/DYNC1H1 pathway in NSCLC development. Finally, xenograft tumors were generated in nude mice to validate the mechanism involved. KLF1, LINC02159, and DYNC1H1 were upregulated in NSCLC tissues and cells. KLF1 overexpression promoted NSCLC cell proliferation and invasion, whereas KLF1 knockdown inhibited NSCLC cell proliferation and invasion. Mechanistically, KLF1 transcriptionally activated LINC02159, which could recruit the SRSF1 protein and increase DYNC1H1 mRNA stability in the cytoplasm. Combined experiments revealed that LINC02159 and DYNC1H1 overexpression could counteract the inhibitory effect of KLF1 silencing on NSCLC cell proliferation and invasion. KLF1 silencing inhibited tumor growth in vivo by downregulating the LINC02159\DYNC1H1 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.